Glenmark shares on Monday ended 0.68% up at ₹1,600.85 apiece on BSE. New Delhi: Glenmark Pharmaceuticals on Monday said it ...

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the ...

Participants receiving combination therapy had a 42% reduction in the risk of disease progression or death vs those receiving acalabrutinib monotherapy.

Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell ...

Glenmark Pharmaceuticals launches zanubrutinib (Brukinsa), a BTK inhibitor for treating five B-cell malignancies in India, ...

Glenmark Pharmaceuticals is set to launch zanubrutinib in India, following its approval from the Drugs Controller General of ...

Glenmark Pharmaceuticals rose 1% to Rs 1605.80 after the drug maker announced the upcoming launch of zanubrutinib in India, following approval from the Drugs Controller General of India (DCGI).

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI).

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Researchers observed inequities in receipt of first-line preferred therapies among a cohort of patients with chronic ...